表紙
市場調査レポート

全身性エリテマトーデス (SLE) 治療薬の世界市場:2015年〜2019年

Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 328872
出版日 ページ情報 英文 83 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
全身性エリテマトーデス (SLE) 治療薬の世界市場:2015年〜2019年 Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019
出版日: 2015年04月22日 ページ情報: 英文 83 Pages
概要

世界の全身性エリテマトーデス (SLE) 治療薬の市場は2014年から2019年にかけて22.41%のCAGRで成長すると予測されています。

当レポートでは、全身性エリテマトーデス (SLE) 治療薬の市場について調査し、市場および主な製品の概要、疾患の概要、パイプラインの状況、薬剤タイプ・薬剤クラス・地域別の市場分析、市場規模の推移と予測、市場成長への各種影響因子の分析、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 略語一覧

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

第5章 イントロダクション

第6章 疾患概要

第7章 SLE治療薬のパイプラインの状況

第8章 市場環境

  • 市場概要
  • 市場規模・予測
  • 南北アメリカ
    • 市場規模・予測
  • 欧州
    • 市場規模・予測

第9章 Benlysta:市場評価

  • 収益予測:米国
  • 収益予測:EU5カ国
  • ファイブフォース分析

第10章 タイプ別市場

第11章 薬剤クラス別市場

第12章 地域別市場

第13章 購入基準

第14章 市場成長推進要因

第15章 推進要因とその影響

第16章 市場課題

第17章 推進要因および課題の影響

第18章 市場動向

第19章 動向とその影響

第20章 ベンダー環境

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
    • Anthera Pharmaceuticals
    • BMS
    • GSK
    • ImmuPharma
    • Merck Serono
    • UCB
  • その他の有力ベンダー

第21章 主要ベンダーの分析

  • Anthera Pharmaceuticals
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • ImmuPharma
  • Merck Serono
  • UCB
    • 主要データ
    • 事業概要
    • 部門別収益
    • 地域別収益
    • 事業戦略
    • 近年の発展動向
    • SWOT分析、など

第22章 関連レポート

図表

目次
Product Code: IRTNTR5703

About SLE

SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.

TechNavio's analysts forecast the Global SLE Drugs market to grow at a CAGR of 22.41 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global SLE Drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of SLE that are available in the market.

TechNavio's report, the Global SLE Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA; it covers the Global SLE Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Anthera Pharmaceuticals
  • BMS
  • GSK
  • ImmuPharma
  • Merck Serono
  • UCB

Other Prominent Vendors

  • Amgen
  • HGS
  • Immunomedics
  • Johnson & Johnson
  • MedImmune
  • Sanofi
  • Teva Pharmaceutical Industries

Market Driver

  • High Prevalence of Autoimmune Disease
  • For a full, detailed list, view our report

Market Challenge

  • Complex Etiology
  • For a full, detailed list, view our report

Market Trend

  • Increase in Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market overview
  • 03.2. Product offerings

04. Market Research Methodology

  • 04.1. Market research process
  • 04.2. Research methodology

05. Introduction

06. Disease Overview

  • 06.1. Etiology
  • 06.2. Epidemiology
  • 06.3. Risk factors
  • 06.4. Quality of life
  • 06.5. Symptoms
  • 06.6. Diagnosis
  • 06.7. Management and treatment

07. SLE Pipeline Landscape

08. Market Landscape

  • 08.1. Market overview
  • 08.2. Market size and forecast
  • 08.3. SLE drugs market in Americas
    • 08.3.1. Market size and forecast
  • 08.4. SLE drugs market in Europe
    • 08.4.1. Market size and forecast

09. Market Assessment of Benlysta

    • 09.1.1. Benlysta revenue forecast in US
    • 09.1.2. Benlysta revenue forecast in 5EU
  • 09.2. Five forces analysis

10. Market Segmentation by Type

11. Market Segmentation by Therapeutic Class

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive scenario
    • 20.1.1. Key news
    • 20.1.2. Mergers and acquisitions
  • 20.2. Market share analysis 2014
    • 20.2.1. Anthera Pharmaceuticals
    • 20.2.2. BMS
    • 20.2.3. GSK
    • 20.2.4. ImmuPharma
    • 20.2.5. Merck Serono
    • 20.2.6. UCB
  • 20.3. Other prominent vendors

21. Key Vendor Analysis

  • 21.1. Anthera Pharmaceuticals
    • 21.1.1. Key facts
    • 21.1.2. Business overview
    • 21.1.3. Business strategy
    • 21.1.4. Recent developments
    • 21.1.5. SWOT analysis
  • 21.2. Bristol-Myers Squibb
    • 21.2.1. Key facts
    • 21.2.2. Business overview
    • 21.2.3. Key product offerings
    • 21.2.4. Revenue by geography
    • 21.2.5. Business strategy
    • 21.2.6. Key information
    • 21.2.7. SWOT analysis
  • 21.3. GlaxoSmithKline
    • 21.3.1. Key facts
    • 21.3.2. Business overview
    • 21.3.3. Business segmentation
    • 21.3.4. Business segmentation by revenue 2012 and 2013
    • 21.3.5. Sales by geography
    • 21.3.6. Pipeline products
    • 21.3.7. Business strategy
    • 21.3.8. Key information
    • 21.3.9. SWOT analysis
  • 21.4. ImmuPharma
    • 21.4.1. Key facts
    • 21.4.2. Business overview
    • 21.4.3. Business strategy
    • 21.4.4. Recent developments
    • 21.4.5. SWOT analysis
  • 21.5. Merck Serono
    • 21.5.1. Key facts
    • 21.5.2. Business overview
    • 21.5.3. Geographical segmentation by revenue 2013
    • 21.5.4. Business strategy
    • 21.5.5. Recent developments
    • 21.5.6. SWOT analysis
  • 21.6. UCB
    • 21.6.1. Key facts
    • 21.6.2. Business overview
    • 21.6.3. Product segmentation by revenue 2013
    • 21.6.4. Product segmentation by revenue 2012 and 2013
    • 21.6.5. Geographical segmentation by revenue 2013
    • 21.6.6. Business strategy
    • 21.6.7. Recent developments
    • 21.6.8. SWOT analysis

22. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market research methodology
  • Exhibit 2: Diagnosed prevalent cases of SLE 2014 and 2019
  • Exhibit 3: Overview of management of SLE
  • Exhibit 4: Global SLE drugs market 2014-2019 ($ million)
  • Exhibit 5: SLE drugs market in Americas 2014-2019 ($ million)
  • Exhibit 6: SLE drugs market in Europe 2014-2019 ($ million)
  • Exhibit 7: Benlysta: Global revenue 2011-2013 ($ million)
  • Exhibit 8: Benlysta: Revenue forecast in US 2014-2019 ($ million)
  • Exhibit 9: Benlysta: Revenue forecast in 5EU 2014-2019 ($ million)
  • Exhibit 10: Segmentation of global SLE drugs market by type
  • Exhibit 11: Segmentation of global SLE drugs market by therapeutic class
  • Exhibit 12: Segmentation of global SLE drugs market by geography 2014
  • Exhibit 13: Orencia: Global revenue 2011-2013 ($ million)
  • Exhibit 14: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 15: Bristol-Myers Squibb: Revenue by geographical segmentation 2013
  • Exhibit 16: GlaxoSmithKline: Business segmentation 2013
  • Exhibit 17: GlaxoSmithKline: Business segmentation by revenue 2012 and 2013 (US$ billion)
  • Exhibit 18: GlaxoSmithKline: Sales by geography 2013
  • Exhibit 19: GlaxoSmithKline: Pipeline products 2013
  • Exhibit 20: Merck Serono: Geographical segmentation by revenue 2013
  • Exhibit 21: UCB: Product segmentation by revenue 2013
  • Exhibit 22: UCB: Product segmentation by revenue 2012 and 2013 (US$ million)
  • Exhibit 23: UCB: Geographical segmentation by revenue 2013
Back to Top